7 news items
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
ARVN
17 Jun 24
natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple
Arvinas to Participate in Upcoming Investor Conferences
ARVN
3 Jun 24
, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
ARVN
23 May 24
targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)
ARVN
PFE
16 May 24
of ESR1 mutation status." Vepdegestrant is an investigational PROTAC ER degrader designed to harness the body's natural protein disposal
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
ARVN
9 May 24
degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease
d4w3p54smmqc9
ARVN
NVS
7 May 24
to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its
7llhxoidjdi3t rew7rbpjbuz11wgt6zesig8xlopje39i
ARVN
2 May 24
degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing
- Prev
- 1
- Next